NASDAQ: CINGCingulate Inc Stock
$0.92-0.01 (-1.08%)
Updated Mar 20, 2023
CING Price
$0.92
Fair Value Price
N/A
Market Cap
$10.35M
52 Week Low
$0.66
52 Week High
$2.15
P/E
-0.59x
P/B
2.67x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.94
Operating Cash Flow
-$16M
Beta
1.17
Next Earnings
May 12, 2023
Ex-Dividend
N/A
Next Dividend
N/A
CING Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for attention deficit/hyperactivity disorder. The company's lead candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). CTx-2103 is being developed for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, KS.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CING scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CING is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CING is good value based on its book value relative to its share price (2.67x), compared to the US Biotechnology industry average (4.81x)
P/B vs Industry Valuation
CING is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CING due diligence checks available for Premium users.
Be the first to know about important CING news, forecast changes, insider trades & much more!
CING News
Valuation
CING fair value
Fair Value of CING stock based on Discounted Cash Flow (DCF)
Price
$0.92
Fair Value
$2.28
Undervalued by
59.58%
CING is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CING price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.59x
Industry
16.1x
Market
22.37x
CING price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.67x
Industry
4.81x
CING is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CING's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.6M
Profit Margin
0%
CING's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$7.5M
Debt to equity
1.94
CING's short-term assets ($7.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CING's short-term assets ($7.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CING's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
-$143.0k
Financing
-$89.8k
CING's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CING vs Biotech Stocks
Cingulate Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.